ENTPD1 and neoplasm: While targeting other potential immune checkpoints, small molecules or antibodies that disrupt negative regulation between tumor cells and T cells or between bone marrow cells and T cells, such as LAG3, TIGIT, TIM3, B7H3, CD39, CD73, and Adenosine A2A receptors, are in clinical trials [172].